Administration of Iranian Propolis attenuates oxidative stress and blood glucose in type II diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial.
Catalase activity
Fructosamine
Oxidized-LDL
Propolis
Type 2 diabetes mellitus
Journal
Caspian journal of internal medicine
ISSN: 2008-6164
Titre abrégé: Caspian J Intern Med
Pays: Iran
ID NLM: 101523876
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
13
3
2019
pubmed:
13
3
2019
medline:
13
3
2019
Statut:
ppublish
Résumé
Hyperglycemia in diabetic people resulted in oxidative conditions. Propolis is the third most important component of bee products which has various functional properties such as anti-oxidant due to its components. The aim of this study was to evaluate the propolis effect on fructosamine level, the catalase activity, and the level of oxidized LDL changes in type 2 diabetic patients. In this double-blind, randomized controlled trial study, 62 type 2 diabetic patients, attending Endocrine clinic in Velayat Hospital (Qazvin, Iran) in 2017, were randomly assigned to one of intervention and placebo (n=31) groups. Participants in intervention group took propolis capsule (500 mg) 3 times a day and those in placebo group took placebo capsules for 8-week. Fructosamine level, catalase activity and the level of oxidized-LDL were measured at the baseline and at the end of the study. Statistical analysis was performed using SPSS software. At the end of the study, significant differences were seen within groups and in-between groups. In Propolis group compared to the placebo, fructosamine (p<0.05), and the level of oxidized LDL (p<0.05) decreased, and catalase activity (p<0.05) improved. However, there were no significant changes in the placebo group at the end of trial. Eight weeks intake of propolis as a supplement in type II diabetic patients could improve anti-oxidant defense and decline production of hyperglycemia induced products such as fructosamine.
Sections du résumé
BACKGROUND
BACKGROUND
Hyperglycemia in diabetic people resulted in oxidative conditions. Propolis is the third most important component of bee products which has various functional properties such as anti-oxidant due to its components. The aim of this study was to evaluate the propolis effect on fructosamine level, the catalase activity, and the level of oxidized LDL changes in type 2 diabetic patients.
METHODS
METHODS
In this double-blind, randomized controlled trial study, 62 type 2 diabetic patients, attending Endocrine clinic in Velayat Hospital (Qazvin, Iran) in 2017, were randomly assigned to one of intervention and placebo (n=31) groups. Participants in intervention group took propolis capsule (500 mg) 3 times a day and those in placebo group took placebo capsules for 8-week. Fructosamine level, catalase activity and the level of oxidized-LDL were measured at the baseline and at the end of the study. Statistical analysis was performed using SPSS software.
RESULTS
RESULTS
At the end of the study, significant differences were seen within groups and in-between groups. In Propolis group compared to the placebo, fructosamine (p<0.05), and the level of oxidized LDL (p<0.05) decreased, and catalase activity (p<0.05) improved. However, there were no significant changes in the placebo group at the end of trial.
CONCLUSION
CONCLUSIONS
Eight weeks intake of propolis as a supplement in type II diabetic patients could improve anti-oxidant defense and decline production of hyperglycemia induced products such as fructosamine.
Identifiants
pubmed: 30858941
doi: 10.22088/cjim.10.1.48
pmc: PMC6386327
doi:
Types de publication
Journal Article
Langues
eng
Pagination
48-54Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Arterioscler Thromb Vasc Biol. 2001 May;21(5):844-8
pubmed: 11348884
Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1162-7
pubmed: 12117732
Pharmacol Res. 2005 Feb;51(2):147-52
pubmed: 15629260
J Ethnopharmacol. 2005 Aug 22;100(1-2):114-7
pubmed: 15993016
J Gerontol A Biol Sci Med Sci. 2007 Apr;62(4):427-33
pubmed: 17452738
Curr Pharm Des. 2007;13(36):3688-95
pubmed: 18220807
Biochimie. 2011 Apr;93(4):645-58
pubmed: 21167901
Diabetes Metab J. 2013 Apr;37(2):106-12
pubmed: 23641350
Evid Based Complement Alternat Med. 2013;2013:697390
pubmed: 23737843
Dermatitis. 2013 Nov-Dec;24(6):263-82
pubmed: 24201459
Evid Based Complement Alternat Med. 2014;2014:465383
pubmed: 24864152
Can J Diabetes. 2015 Feb;39(1):44-9
pubmed: 25065473
J Exerc Nutrition Biochem. 2014 Mar;18(1):9-17
pubmed: 25566434
Crit Rev Toxicol. 2015;45(9):765-98
pubmed: 26610815
Physiol Rev. 2016 Jan;96(1):307-64
pubmed: 26681794
J Diabetes Investig. 2016 Jul;7(4):506-13
pubmed: 27181714
Pharmacol Ther. 2017 Apr;172:50-62
pubmed: 27916650
Biosens Bioelectron. 2017 Jul 15;93:9-13
pubmed: 28073620
J Integr Med. 2017 Mar;15(2):124-134
pubmed: 28285617
Diabetes Res Clin Pract. 2017 Jun;128:40-50
pubmed: 28437734
Evid Based Complement Alternat Med. 2017;2017:4272940
pubmed: 28539963
Biomed Pharmacother. 2017 Aug;92:1085-1094
pubmed: 28622709
Sci Rep. 2017 Jul 31;7(1):6886
pubmed: 28761149
Oxid Med Cell Longev. 2017;2017:1259510
pubmed: 28814983
Diabetes Care. 2018 Mar;41(3):570-576
pubmed: 29208654
Diabetes Ther. 2018 Feb;9(1):101-111
pubmed: 29214374
Diabetes Res Clin Pract. 2018 Mar;137:160-172
pubmed: 29329777
Biomed Res Int. 2017;2017:7989180
pubmed: 29362717
Cell Death Dis. 2018 Jan 25;9(2):119
pubmed: 29371661
Evid Based Complement Alternat Med. 2018 Mar 11;2018:4360356
pubmed: 29713363
J Nutr Biochem. 2018 Jul;57:206-211
pubmed: 29753234